Regimens like acalabrutinib plus venetoclax allow clinicians to start one drug and add the second months later. This flexibility accommodates patients' personal schedules, such as planned travel, making treatment initiation easier and improving the patient experience without compromising the regimen's core structure.

Higher death rates observed in the triplet therapy arms of recent CLL trials (e.g., AMPLIFY) were significantly impacted by the COVID-19 pandemic, as anti-CD20 antibodies increase infection risk. This historical context complicates the interpretation and generalizability of the toxicity data in a post-pandemic era.

Adding obinutuzumab to acalabrutinib/venetoclax (triplet therapy) deepens responses but led to higher death rates in trials, partly due to COVID-19. This makes it a high-risk, high-reward strategy that experts reserve for younger, healthier patients with high-risk disease who prioritize coming off therapy.

Adding obinutuzumab later to acalabrutinib/venetoclax therapy—and only for patients with an incomplete response—achieves the same remission rates as upfront administration. This delayed approach improves overall survival by avoiding early, severe infections, particularly COVID-19, associated with the antibody.

With highly effective CLL therapies, primary causes of mortality are now infections and secondary cancers from immunodeficiency. Research is now focusing on immune reconstitution after treatment, marking a pivotal shift towards managing long-term survivorship challenges beyond just controlling the leukemia itself.

Three-year data for odronextumab, given until progression in follicular lymphoma, reveals a high rate of severe (Grade 3+) infections (45%), including fatal events. This highlights a critical safety concern with continuous dosing and strengthens the clinical argument for using fixed-duration bispecific regimens to mitigate long-term toxicity.

Despite the individual high efficacy of both BCMA-directed therapies and anti-CD38 antibodies, there is significant clinical concern about combining them. The potential for compounded immunosuppression and severe infection risk is a major barrier shaping clinical trial design and favoring sequential use over concurrent combination.

An MD Anderson study suggests adding obinutuzumab later in treatment only for patients failing to achieve undetectable MRD, rather than upfront for all. This "delayed add-on" strategy improves the safety profile by reducing rates of severe infection and neutropenia while reserving the potent antibody for patients who need it most.

While adding a menin inhibitor to the azacitidine/venetoclax doublet for older/unfit AML patients increases response rates, it leaves little reserve for marrow function. This can lead to increased risk of early, fatal complications like infection or bleeding, requiring careful dose management.